

Fibromyalgia Undertreated, Despite Therapies

BY SALLY KOCH KUBETIN

SANTA MONICA, CALIF. — Effective treatments exist for fibromyalgia syndrome, but many physicians still do a poor job of treating affected patients, according to Dr. Chad S. Boomershine.

Could it be that these physicians don't consider fibromyalgia to be a "real" disease, that they perceive affected patients as being too time consuming and un-

likely to get better? asked Dr. Boomershine, a rheumatologist at Vanderbilt University in Nashville, Tenn., where he specializes in treating fibromyalgia in collaboration with the Vanderbilt Center for Integrative Health and the Vanderbilt Dayani Center.

About 2%-4% of the U.S. population meet the fibromyalgia classification criteria issued in 1990 by the American College of Rheumatology. The true prevalence is

estimated to be about twice as high.

The ACR classification criteria for fibromyalgia include widespread pain for at least 3 months' duration, and pain at a minimum of 11 of 18 specified tender points when enough pressure to just blanch the examiner's thumbnail is applied. The reported 9:1 ratio of women to men with the condition is incorrect, he said, as women have more tender points and men are more likely to self-medicate

rather than to seek medical care.

Fibromyalgia typically involves symptoms other than pain, which Dr. Boomershine teaches using the FIBRO mnemonic (F for fatigue and 'fibrofog' [cognitive dysfunction], I for insomnia [nonrestorative sleep], B for blues [depression and anxiety], R for rigidity [muscle and joint stiffness], and O for Ow! [pain and work disability]). Nevertheless, pharmacologic management should

Advise Patients To Get Moving

Although effective medications are available, it takes more than drug therapy to manage fibromyalgia, according to Dr. Chad S. Boomershine.

"I recommend patients perform stretches every morning and, on alternating days, engage in aerobic and resistance exercise a total of 6 days per week," he said.

"The combination of aerobic and resistance exercise is particularly effective in improving symptoms. Since many patients don't live near an exercise facility, I provide patients with instructional handouts and [professional elastic resistance bands] for resistance exercise on their initial visit so they can exercise at home," the rheumatologist from Vanderbilt University added.

Dr. Boomershine said he refers his patients to the exercise guide on the National Institute on Aging Web site (www.nia.nih.gov/HealthInformation/Publications/ExerciseGuide).

He also recommends the National Center on Physical Activity and Disability Web site for access to an exercise fact sheet that's helpful for younger patients (www.ncpad.org/exercise/fact_sheet.php?sheet=259).

Additionally, he recommends that patients learn more about fibromyalgia and find support groups in their area.

"Due to the severity of their symptoms, patients are often afraid they have a terminal illness," he noted. "Understanding that fibromyalgia is not progressive and realizing they can manage their symptoms by learning self-help techniques is empowering and necessary if patients are to have lasting symptom improvement."

The Web sites www.knowfibro.com and www.fmaware.org can provide additional information, said Dr. Boomershine, who also cowrote a treatment review article that he said clinicians might find helpful (*Nat. Rev. Rheumatol.* 2009;5:191-9).

NEW INDICATION

In high-risk* patients who are unable to take an ACE-I,

DOOM

REDUCE THE RISK OF MI, STRO

Important Safety Information

WARNING: AVOID USE IN PREGNANCY

When used in pregnancy, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, MICARDIS® (telmisartan) tablets should be discontinued as soon as possible (See Warnings and Precautions).

- MICARDIS is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
- MICARDIS is indicated for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.
- High risk for cardiovascular events can be evidenced by a history of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or high-risk diabetes (insulin dependent or non-insulin dependent) with evidence of end-organ damage. MICARDIS can be used in addition to other needed treatment (such as antihypertensive, antiplatelet, lipid-lowering therapy, etc).
- Studies of telmisartan in this setting do not exclude that it may not preserve a meaningful fraction of the effect of the ACE inhibitor to which it was compared. Consider using the ACE inhibitor first, and, if it is stopped for cough only, consider retrying the ACE inhibitor after the cough resolves.
- Use of telmisartan with an ACE inhibitor is not recommended.
- Volume depletion and/or salt depletion should be corrected in patients before initiation of therapy or start treatment under close medical supervision with a reduced dose, otherwise symptomatic hypotension may occur.
- In patients with impaired hepatic function, initiate telmisartan at low doses and titrate slowly.
- Monitor carefully in patients with impaired renal function, especially in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe congestive heart failure or renal dysfunction); treatment of these patients with ACE inhibitors and ARBs has been associated with oliguria and/or progressive azotemia and, rarely, with acute renal failure and/or death. In patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen may occur.
- Dual blockade of the renin-angiotensin-aldosterone system (eg, by adding an ACE-inhibitor to an ARB) should include close monitoring of renal function. Use of MICARDIS with ramipril is not recommended.

Please see Brief Summary of Prescribing Information on following pages.

start by treating pain because it is the one symptom common to all fibromyalgia patients, he said. When choosing among the three indicated medications, individualize therapy based on the associated symptom that is most disabling for the patient, Dr. Boomershine said at a meeting sponsored by RHEUMATOLOGY NEWS and Skin Disease Education Foundation.

Pain associated with insomnia is best treated with pregabalin (Lyrica), he said. The label states that pregabalin should be given in two divided doses daily beginning with a total of 150 mg/day and increasing to as much as 450 mg/day if

needed. In an effort to avoid the typical side effects of dizziness, somnolence, fa-



Management should start by treating pain because it is the one symptom common to all patients.

DR. BOOMERSHINE

tigue, and cognitive dysfunction, however, Dr. Boomershine recommends be-

ginning with 25-75 mg once daily at bedtime and titrating up to 150-225 mg at night before adding a morning dose.

Pain with depression and/or anxiety is best managed with duloxetine (Cymbalta) every morning, he said. The label states that the recommended dosage for fibromyalgia is 60 mg/day, but Dr. Boomershine recommends starting with 20-30 mg and increasing to 60 mg only if necessary. Trial data indicate that many patients do well on lower doses, he noted, and higher doses are associated with increased risk for side effects.

For pain associated with fatigue, the

treatment of choice is milnacipran (Savella), he said. The label for this agent recommends starting at a dose of 12.5 mg once daily and gradually working up to 50 mg twice daily after 1 week and a maximum dosage of 100 mg twice daily. But Dr. Boomershine recommends titrating the dosage up more gradually.

Dr. Boomershine is an investigator for Pfizer Inc. and the National Institutes of Health, and is a consultant for Pfizer, Eli Lilly & Co., Forest Pharmaceuticals Inc., and Takeda Pharmaceutical Co.

SDEF and this news organization are owned by Elsevier. ■



KE, OR DEATH FROM CV CAUSES

ACE-I: Angiotensin-converting enzyme inhibitor. MI: Myocardial infarction. CV: Cardiovascular. ARB: Angiotensin receptor blocker.

MICARDIS 80 mg is now the only ARB proven to reduce CV risk in high-risk patients who are unable to take an ACE-I.

Supported by ONTARGET and TRANSCEND, two studies in a large-scale clinical program with entry criteria similar to those used in the HOPE trial with ramipril—MICARDIS® (telmisartan) 80 mg tablets reduce MI, stroke, or death from CV causes in a broad range of high-risk patients with or without hypertension.¹⁻³

*High risk is evidenced by a history of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or high-risk diabetes (insulin dependent or non-insulin dependent) with evidence of end-organ damage.

MICARDIS
(telmisartan) tablets **80 mg**



DO MORE TO REDUCE CV RISK.

References: 1. Micardis Pl. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2009. 2. Teo K, Yusuf S, Sleight P, et al; and the ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. *Am Heart J*. 2004;148:52-61. 3. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; and the HOPE Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med*. 2000;342:145-153.

Copyright © 2010, Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. Printed in U.S.A. (02/10) MC72412PROF